Prulifloxacin
|
|
|
- CAS-Nr.
- 123447-62-1
- Englisch Name:
- Prulifloxacin
- Synonyma:
- nm441;Sword;Pruvel;Quisnon;CS-1352;AF 3012;Plumfloxacin;PRULIFLOXACIN;Prulifloxacine;Prulioxacin-d8
- CBNumber:
- CB5474525
- Summenformel:
- C21H20FN3O6S
- Molgewicht:
- 461.46
- MOL-Datei:
- 123447-62-1.mol
|
Prulifloxacin Eigenschaften
- Schmelzpunkt:
- 211-214°C
- Siedepunkt:
- 633.2±65.0 °C(Predicted)
- Dichte
- 1.62±0.1 g/cm3(Predicted)
- storage temp.
- Sealed in dry,Store in freezer, under -20°C
- Löslichkeit
- 1 M NaOH: soluble25ML, clear, colorless (Solvent: 1 mg + 25 mL of NaOH)
- pka
- 5.85±0.40(Predicted)
- Aggregatzustand
- White to yellow crystalline solid.
- Farbe
- Off-White to Pale Yellow
- maximale Wellenlänge (λmax)
- 276nm(H2O)(lit.)
- Merck
- 14,7908
- CAS Datenbank
- 123447-62-1(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| RTECS-Nr. |
XJ0600000 |
|
|
| HS Code |
2941.90.3000 |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
Prulifloxacin Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Prulifloxacin was launched as the third fluoroquinone. It was introduced in
Japan as an oral treatment for urinary tract infections (UTls), respiratory tract infections
(RTls) and bacterial pneumoniae. It can be synthesized in 10 steps from commercially
available 3,4-difluoroaniline. Key steps involve the cyclization of 6,7-difluoro-rl-hydroxy-2-
thioquinoline-3carboxylic acid ethyl ester with 1 ,I-dibromomethane to give the
corresponding thiazeto-[3,2a]quinoline. Aromatic nucleophilic substitution of the 7-fluoro
atom with piperazine followed by hydrolysis of the ethyl ester and finally alkylation of the
piperazinyl moiety with 4-(bromomethyl)-5-methyl-l ,bdioxol-Bone complete the synthesis.
Prulifloxacin is a lipophilic prodrug, which is rapidly hydrolyzed to the corresponding Ndealkylated
piperazine, NM 394, by paraoxonase type enzymes in blood and liver following
intestinal absorption. The DNA gyrase inhibitor NM 394 accounts for all antimicrobial
activity: it shows a similar or greater activity against gram-positive bacteria compared to
ciprofloxacin, and a greater activity in the case of gram-negative bacteria. In clinical
studies, prulifloxacin has shown good efficacy against UTls and RTls. The drug is mainly
excreted in the urine and in the feces as unchanged NM 394, which has a plasma half-life
of approximately 8 h. Phototoxicity in animal models is less severe than with other
quinolones. Prulifloxacin is well tolerated with an adverse effect profile similar to that of
other fluoroquinolones.
Chemische Eigenschaften
Off-White Solid
Verwenden
Prulifloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class. Prulifloxacin is a prodrug for active metabolite, Ulifloxacin. Antibacterial.
Pharmazeutische Anwendungen
A lipophilic prodrug which is very rapidly metabolized by esterase into ulifloxacin, a 6-fluoro, 7-piperazinyl thiazetoquinoline.
Ulifloxacin is moderately active against Staph. aureus (MIC 0.4–0.8 mg/L) and inactive against Str. pneumoniae (MIC 2–8 mg/L) as well as against Enterococcus spp. Against Enterobacteriaceae (MIC 0.05–0.8 mg/L) and Ps. aeruginosa (MIC 0.2–0.8 mg/L) activity is similar to that of ciprofloxacin. It is active against fastidious Gram-negative bacilli, but not against anaerobes and non-fermentative Gram-negative bacilli. Activity against Acinetobacter spp. is modest.
Prulifloxacin is rapidly converted into ulifloxacin and after 3 h is no longer detected in blood. In volunteers receiving a single oral dose, peak plasma concentrations of 0.68 mg/L (300 mg dose) to 1.88 mg/L (for 400 mg dose) were attained between 0.67 and 1.25 h. The mean apparent elimination half-life was 8 h and the mean cumulative elimination rate in urine within 48 h was 31–46%. Other inactive metabolites account for 7% of the dose. Half the administered dose is eliminated in feces within 72 h as ulifloxacin and 4% as prulifloxacin. Protein binding is 45%.
Prulifloxacin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Prulifloxacin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 317)Lieferanten
123447-62-1()Verwandte Suche:
2-(3,6-Dihydroxy-2,4,5,7-tetrabromxanthen-9-yl)-benzoesure
Methylsalicylat
Thiophanat-methyl
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
Moxifloxacin
Norfloxacin
Ciprofloxacin
Ofloxacin
Tribenuron methyl
Rimantadine
2,2,6,6-Tetramethylpiperidin-4-ol
2,2,6,6-Tetramethylpiperidinooxy
Levofloxacin hydrochloride
Kresoxim-methyl
Cyclopenten
POLY(METHYLSILSESQUIOXANE)
2-[[[[(4-Methoxy-6-methyl-1,3,5-triazin-2-yl)amino]carbonyl]amino]sulfonyl]benzoic acid methyl ester
Methyl
- 1h,4h-(1,3)thiazeto(3,2-a)quinoline-3-carboxylicacid,6-fluoro-1-methyl-7-(4-(
- 3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo-(5-methyl-2-oxo-
- nm441
- Prulifloxacine
- PRULIFLOXACIN(FORRESEARCHONLY)
- (+/-)-7-{4-[(Z)-2,3-Dihydroxy-2-butenyl]-1-piperazinyl}-6-fluoro-1-methyl-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid cyclic carbonate
- 6-Fluoro-1-methyl-7-(4-(5-methyl-2-oxo-1,3-dioxelen-4-yl)methyl-1-piperazinyl)-4-oxo-4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid
- PRULIFLOXACIN
- SEA BUCKTHORN P.E 20%
- 6-Fluoro-1-Methyl-7-[4-[(5-Methyl-2-oxo-1,3-dioxol-4-yl)Methyl]-1-piperazinyl]-4-oxo-
- Quisnon
- Sword
- Prulifloxacin (Pruvel)
- Prulifloxacin,6-Fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid, NM441
- 6-fluoro-1-Methyl-7-(4-(5-Methyl-2-oxo-1,3-dioxelen-4-yl)Methyl-1-piperazinyl)-4-oxo-4h-(1,3)thiazeto(3
- 6-Fluoro-1-Methyl-7-(4-((5-Methyl-2-oxo-1,3-dioxol-4-yl)Methyl)piperazin-1-yl)-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
- Prulioxacin-d8
- Prulifloxacin
(+/-)-7-{4-[(Z)-2,3-Dihydroxy-2-butenyl]-1-piperazinyl}-6-fluoro-1-methyl-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid cyclic carbonate
- 6-Fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
- (1R)-6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
- Prulifloxacin(NM441,AF3013)
- CS-1352
- Prulifloxacin, NM 441
- Pruvel
- PRULIFLOXACIN 99%
- Prulifloxacin>
- AF 3012
- 1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-
- hot selling Prulifloxacin
- Prulifloxacin USP/EP/BP
- Prulifloxacin Polymorph I
DISCONTINUED PLEASE SEE P838885
- Prulifloxacin Polymorph II
DISCONTINUED PLEASE SEE P838885
- PrulifloxacinQ: What is
Prulifloxacin Q: What is the CAS Number of
Prulifloxacin Q: What is the storage condition of
Prulifloxacin Q: What are the applications of
Prulifloxacin
- TIANFUCHEM--123447-62-1--Prulifloxacin
- PrulifloxacinCAS
- Plumfloxacin
- Dipivefrine Hydrochloride Impurity 5 (Dipivefrine Hydrochloride EP Impurity E)
- Prulifloxacin, ≥ 98.0%
- 123447-62-1
- 6123447-62-1
- API
- Other Products
- Aromatics
- Heterocycles
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Sulfur & Selenium Compounds
- QUISNON
- 123447-62-1
- Coronavirus
